ArticleCellular oncology (Dordrecht, Netherlands)2025
Unraveling the miR-144-3p/PUMA pathway: a novel regulator of FDX1-mediated cuproptosis in colorectal cancer.
Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities.Journal of hematology & oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeCuproptosis represents a novel form of cell death, predominantly driven by excessive intracellular accumulation of Cu+. The mechanisms underlying cuproptosis in colorectal cancer (CRC) remain unknown. This study aims to investigate the underlying mechanisms in CRC, offering a novel therapeutic strategy for its treatment.
methodsTranscriptomic datasets from The Cancer Genome Atlas (TCGA) databases were analyzed using R-software (v4.3.1) to quantify miR-144-3p expression in CRC. In vitro, CCK-8, EdU, colony formation assays, and Transwell assays were used to assess the proliferative capacity, migratory potential, and invasive properties of CRC under miR-144-3p modulation. Western blotting (WB) further linked miR-144-3p expression to modulation of cuproptosis-related pathways. RNA immunoprecipitation (RIP) and dual-luciferase reporter assays were performed to validate miR-144-3p binding to the 3′-UTR of PUMA mRNA. Co-IP and Immunofluorescence (IF) assays confirmed PUMA-FDX1 binding. DLAT oligomerization was analyzed by WB and IF experiments. The ubiquitination level of FDX1 was detected via Co-IP. In vivo, tumor xenograft experiments using HCT116OE − miR−144−3p and HCT116sh − miR−144−3p cell lines were performed in nude mice.
resultsIn this study, miR-144-3p, a recently identified microRNA, was found to be aberrantly upregulated in CRC. It significantly promoted the proliferation, migration, and invasion of CRC both in vitro and in vivo. Mechanistically, miR-144-3p directly bound to the 3′-UTR of PUMA mRNA, thereby inhibiting PUMA expression and function, which restrained cell death. Furthermore, PUMA induces cuproptosis by enhancing the function of FDX1 through the directly binding with its R155 site, which promotes the oligomerization of lipoylated DLAT/DLST and reduces LIAS expression. In addition, we identified the way in which FDX1 is depleted in the process of cuproptosis: the binding between PUMA and FDX1 raised the ubiquitination level at the K182 site, leading to the further degradation of FDX1.
conclusionsOur findings delineate a miR-144-3p/PUMA regulatory axis controlling cuproptosis homeostasis in CRC. PUMA acts as a functional regulator of cuproptosis, activating copper-dependent cell death by binding FDX1, thereby enhancing DLAT/DLST oligomerization and suppressing LIAS expression. This axis may offer a promising new approach and target for the treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.